Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of
nitric oxide synthase, being involved in endothelial dysfunction. Furthermore, ADMA levels have been shown to predict future cardiovascular events in patients with coronary risk factors, such as diabetes and
hypertension. We have previously found that
glyceraldehyde-derived
advanced glycation end products (glycer-AGEs) stimulate ADMA generation in vitro and the levels are associated with ADMA, endothelial dysfunction, and vascular
inflammation in humans. However, it remains unclear what structurally distinct glycer-AGEs are independent correlates of ADMA. In this study, we addressed the issue. We measured serum levels of
protein-bound and free
methylglyoxal-derived hydroimidazolone-1 (MG-H1) and
argpyrimidine, two major structurally identified glycer-AGEs by liquid chromatography-tandem mass spectrometry in 128 outpatients, and examined the correlations of these AGEs, vascular stiffness, and
inflammation with ADMA. Moreover, we examined whether the changes in serum MG-H1 and
argpyrimidine levels after 4-month treatment with oral
hypoglycemic agents (OHAs) were associated with those of ADMA in other 44 patients with
impaired glucose tolerance or
type 2 diabetes. Multiple stepwise regression analysis revealed that
protein-bound MG-H1,
high-density lipoprotein cholesterol (inversely),
high-sensitivity C-reactive protein, and cardio-ankle vascular index were independently correlated with ADMA (R2 = 0.259). Treatment with OHAs significantly decreased ADMA levels in 44
glucose-intolerant or type 2 diabetic patients, and the changes in
protein-bound MG-H1 levels were positively associated with those in ADMA values (p < 0.05). This study demonstrates that serum levels of
protein-bound MG-H1 are independently correlated with ADMA and may be a therapeutic target for
cardiovascular disease.